Outlook Therapeutics, Inc. (OTLK) Q3 2024 Annual Earnings
OTLK·Reported December 27, 2024·Before market open
Diluted EPS came in at $-0.77, beat the $-0.83 consensus by $0.06.
Diluted EPS
$-0.77beat by $0.06
Consensus: $-0.83
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Outlook Therapeutics, Inc.'s Q3 2024 earnings report.
Outlook Therapeutics, Inc. (OTLK) reported Q3 2024 earnings on December 27, 2024 before market open.
Outlook Therapeutics, Inc. reported diluted EPS of $-0.77 for Q3 2024.
EPS beat the consensus estimate of $-0.83 by $0.06.
You can read the 10-K periodic report (0001558370-24-016491) directly on SEC EDGAR. The filing index links above go to sec.gov.